Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Adquey (difamilast) Coverage & Prior Au…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PMN.308

    Difamilast (Adquey) topical for atopic dermatitis

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PMN.308 alerts

    Get alerted when Policy CP.PMN.308 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, and coverage criteria for topical difamilast (Adquey) for members age 2 and older across QualChoice lines of business (Commercial, HIM/ICHRA, Medicaid). Affects providers requesting coverage or continuation of Adquey.

    Policy Summary
    PayerQualChoice
    PolicyDifamilast (Adquey) topical for atopic dermatitis
    Policy CodePolicy CP.PMN.308
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis of atopic dermatitis, age ≥2 years, required topical therapy trials, and dose ≤60 g per 30 days.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥2min age
    60 gmax dose/30d
    12 moapproval duration
    27 g, 85 gpackage sizes
    1%

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    strength

    Coverage Criteria for Difamilast (Adquey)

    Initial Therapy — Covered when ALL of the following are met for Atopic Dermatitis (Initial Approval)

    Covered when ALL of the following are met for Atopic Dermatitis (Initial Approval):

    Atopic Dermatitis initial approval: 1. Diagnosis of atopic dermatitis; 2. Age ≥ 2 years; 3. Failure of a 2-week trial of two generic medium to very high potency topical corticosteroids of different molecular identities, unless contraindicated (e.g., areas involving the face, neck, or intertriginous areas) or clinically significant adverse effects are experienced; 4. Failure of a 2-week trial of topical tacrolimus, unless contraindicated or clinically significant adverse effects are experienced; 5. Dose does not exceed 60 grams per 30 days.

    Illinois HIM requests: step therapy requirements do not apply per IL HB 5395 (see inline notes).

    Continuation Therapy — Continuation of therapy covered when ALL of the following are met

    Continuation of therapy covered when ALL of the following are met:

    Atopic Dermatitis continued therapy: 1. Member meets one of the following: a) currently receiving medication via Centene benefit or previously met initial approval criteria; or b) currently receiving medication and enrolled in a state/product with continuity of care regulations (see state-specific addendums CC.PHARM.03A and CC.PHARM.03B); 2. Member is responding positively to therapy; 3. If request is for a dose increase, new dose does not exceed 60 grams per 30 days.

    Refer to state-specific continuity of care addendums for CC.PHARM.03A and CC.PHARM.03B.

    Non–FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace/ICHRA), or CP.PMN.53 (Medicaid).

    Initial Therapy Requirements

    Initial therapy — Initial therapy criteria for atopic dermatitis

    Initial therapy criteria for atopic dermatitis

    Initial: Diagnosis of atopic dermatitis; age ≥ 2 years; failure of 2-week trials of two generic medium to very high potency topical corticosteroids of different molecular identities unless contraindicated (e.g., face, neck, intertriginous areas) or clinically significant adverse effects; failure of a 2-week trial of topical tacrolimus unless contraindicated or clinically significant adverse effects; dose ≤ 60 g per 30 days.

    Illinois HIM requests: step therapy requirements do not apply per IL HB 5395.

    Initial therapy — Initial dosing for indicated condition

    Initial dosing for indicated condition

    Initial topical dosing: Apply a thin layer to the affected areas twice daily for mild-to-moderate atopic dermatitis.

    Criteria for Continued Therapy

    Continuation — Continued therapy criteria

    Continued therapy criteria

    Continued therapy: Member currently receiving medication via Centene benefit or previously met initial approval criteria or is enrolled in a state/product with continuity of care; member responding positively to therapy; dose increases must not exceed 60 g/30 days.

    Refer to state-specific continuity of care addendums for CC.PHARM.03A and CC.PHARM.03B.

    Provider Requirements and Actions

    Prior Authorization

    Prior authorization required for Adquey

    Prior authorization is required for Adquey (difamilast) and must include documentation demonstrating: a diagnosis of atopic dermatitis, member age ≥ 2 years, completion of the specified prior topical therapy trials (unless contraindicated), and that the requested dose does not exceed 60 grams per 30 days.

    • Diagnosis of atopic dermatitis must be documented.
    • Member age ≥ 2 years must be documented.
    • Prior topical therapy trials as specified in the policy must be documented (see step therapy block).
    • Requested dose must not exceed 60 g per 30 days.
    Step Therapy

    Step therapy: required prior topical treatments

    Approval requires documented failure of specified topical therapies: two separate 2-week trials of different generic medium to very high potency topical corticosteroids (different molecular identities) and a 2-week trial of topical tacrolimus, unless contraindicated or clinically significant adverse effects occurred.

    Step Therapy Requirements

    StepRequirementDuration/Notes
    1Failure of a 2-week trial of two generic medium to very high potency topical corticosteroids of different molecular identities (unless contraindicated, e.g., face, neck, intertriginous areas, or clinically significant adverse effects).2 weeks per corticosteroid; Illinois HIM requests exempt from step therapy per IL HB 5395 (effective 1/1/2026).
    2Failure of a 2-week trial of topical tacrolimus (unless contraindicated or clinically significant adverse effects are experienced).2 weeks; note topical tacrolimus may require prior authorization.

    Coding and Quantity Limits

    inv-04: Maximum topical supply — Dose does not exceed 60 grams per 30 days
    Maximum topical supplyDose does not exceed 60 grams per 30 days.
    Relevant to initial approvalListed as a required condition for initial approval of atopic dermatitis (must meet all criteria).
    Relevant to continuationContinuation requests and any dose increases must not exceed 60 grams per 30 days.

    Quantity Limits and Packaging

    inv-20: Difamilast (Adquey) ointment 1% — 60
    ProductDifamilast (Adquey) ointment 1%.
    Quantity limit60 grams per 30 days (policy quantity limit).
    IndicationTopical treatment for mild to moderate atopic dermatitis in patients ≥2 years.
    inv-21: Difamilast 1% ointment — 27 g or 85 g per package (available sizes)
    Available package sizes27 g per tube.
    Available package sizes85 g per tube.
    Strength1% ointment.

    Background and Drug Information

    Difamilast (Adquey) is a topical phosphodiesterase‑4 (PDE‑4) inhibitor indicated for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients aged ≥ 2 years. The product is supplied as a 1% ointment and is available in package sizes of 27 g and 85 g. For mild‑to‑moderate disease, the prescribing information recommends to apply a thin layer to affected areas twice daily.

    Definitions and Dosing

    inv-14: Adquey (difamilast) — Topical phosphodiesterase-4 inhibitor indicated for mild to moderate atopic dermatitis in patients ≥2 years.
    Drug class and nameAdquey (difamilast) — topical phosphodiesterase-4 inhibitor.
    IndicationIndicated for topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older.
    Therapeutic contextConsidered among topical therapies with alternatives including topical corticosteroids and topical calcineurin inhibitors (policy references).
    inv-15: Apply a thin layer to the affected areas twice daily — Mild-to-moderate atopic dermatitis dosing
    Dosing instructionApply a thin layer to the affected areas twice daily.
    Indication for this dosingMild-to-moderate atopic dermatitis.
    Policy Summary
    PayerQualChoice
    PolicyDifamilast (Adquey) topical for atopic dermatitis
    Policy CodePolicy CP.PMN.308
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis of atopic dermatitis, age ≥2 years, required topical therapy trials, and dose ≤60 g per 30 days.
    SourceLink
    On This Page
    Coverage Criteria for Difamilast (Adquey)Initial Therapy RequirementsCriteria for Continued TherapyProvider Requirements and ActionsStep Therapy RequirementsCoding and Quantity LimitsQuantity Limits and PackagingBackground and Drug InformationDefinitions and Dosing
    • Two 2-week trials of generic medium to very high potency topical corticosteroids of different molecular identities (unless contraindicated).
    • A 2-week trial of topical tacrolimus (unless contraindicated or adverse effects).
    • Illinois HIM requests are exempt from these step therapy requirements per IL HB 5395 (effective 1/1/2026).
    Note

    Step therapy absence (document note)

    Some sections note no step therapy requirements; however, the policy’s initial approval criteria explicitly require specific topical therapy trials (see step therapy block) except where state law exempts HIM requests.

    • The document contains a statement that no step therapy requirements are specified in certain sections, but initial approval criteria do include step therapy requirements (see policy I.A).
    Documentation Required

    Supporting documentation required with PA requests

    Providers must submit supporting clinical documentation with prior authorization requests, such as office chart notes, lab results, or other clinical information demonstrating the member has met all approval criteria.

    • Include office chart notes documenting diagnosis, prior topical therapy trials (dates, agents, duration, response or adverse effects), and age.
    • Include any relevant lab results or other clinical notes supporting contraindications to step agents when applicable.
    Denial Risk

    Denial risk if documentation or criteria not met

    Requests that do not include documentation showing the member meets approval criteria (e.g., diagnosis, required prior topical therapy trials, age) may be denied.

    • Missing documentation of required 2-week trials of topical corticosteroids or topical tacrolimus may result in denial.
    • Missing documentation of diagnosis or age may result in denial.
    Note

    Prior authorization considerations (dosing & product availability)

    Before approval, providers should follow labeled dosing instructions and note product availability when submitting requests: apply a thin layer to affected areas twice daily for mild-to-moderate atopic dermatitis; Adquey ointment 1% is available in 27 g and 85 g packages.

    • Dosing: apply a thin layer to the affected areas twice daily for mild-to-moderate atopic dermatitis.
    • Product availability: Ointment (1%) in 27 g and 85 g package sizes.
    Note

    Supporting references for coverage decisions

    Use the policy references and prescribing information to support coverage decisions and to document rationale when submitting requests.

    • Referenced materials include Adquey Prescribing Information and published atopic dermatitis guidelines cited in the policy.
    Note

    Medicaid coverage precedence

    For Medicaid members, state Medicaid coverage provisions override this clinical policy when there is a conflict; consult the state Medicaid manual for applicable coverage rules.

    • If state Medicaid provisions differ from this policy, the state provisions take precedence for Medicaid members.
    NotesMaximum dose limitations per policy still apply (see quantity limits: 60 g/30 days).